Gonadotrophins for ovulation induction in women with polycystic ovarian syndrome

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 9, 2015, Pages

  Weiss, Nienke S ^a   Nahuis, Marleen ^b   Bayram, Neriman ^c   Mol, Ben Willem J ^d   Van der Veen, Fulco ^e   van Wely, Madelon ^e  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDISCH SPECTRUM TWENTE   (Netherlands)

^c ZAANS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIFENE CITRATE; GONADOTROPIN; RECOMBINANT FOLLITROPIN; CLOMIFENE; FERTILITY PROMOTING AGENT; FOLLITROPIN;

BIRTH RATE; CLINICAL OUTCOME; COMPARATIVE EFFECTIVENESS; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; INCIDENCE; INTRAUTERINE INSEMINATION; LIVE BIRTH; MULTIPLE PREGNANCY; OUTCOME ASSESSMENT; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PREGNANCY RATE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW; TREATMENT DURATION; ABORTION, SPONTANEOUS; CHEMICALLY INDUCED; DRUG RESISTANCE; META ANALYSIS; OVARIAN HYPERSTIMULATION SYNDROME; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ABORTION, SPONTANEOUS; BIRTH RATE; CLOMIPHENE; DRUG RESISTANCE; FEMALE; FERTILITY AGENTS, FEMALE; FOLLICLE STIMULATING HORMONE; GONADOTROPINS; HUMANS; LIVE BIRTH; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY, MULTIPLE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84964695065     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010290.pub2     Document Type: Review

References (50)

1. Balen A, Platteau P, Nyboe Andersen A, Devroey P, Helmgaard L, Arce J. Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II. anovulatory infertility: a randomized controlled non-inferiority trial. Human Reproduction 2007;22(7):1816-23.
2. Coelingh Bennink H, Fauser B, Out H. Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene-resistant, normogonadotropic, chronic anovulation; a prospective, multicenter, assessor-blind, randomized, clinical trial. Fertility and Sterility 1998;69(1):19-25.
3. Feigenbaum SL, Miller P, Kaufmann R, Elkind-Hirsch K, Fein SH, Marshall DC. A new highly purified human-derived FSH, Bravelle, is as effective and well tolerated as recombinant follitropin beta in ovulation induction in infertile women with ovulatory dysfunction. Today's Therapeutic Trends 2001;19(4):297-313.
4. Gadir A, Mofawi R, Alnaser H, Alrashid A, Alonezi O, Shaw R. Ovarian electrocautery versus human menopausal gonadotrophins and pure follicle stimulating hormone therapy in the treatment of patients with polycystic ovarian disease. Clinical Endocrinology 1990;33(5):585-92.
5. Gerli S, Casini ML, Unfer V, Costabile L, Mignosa M, Di Renzo GC. Ovulation induction with urinary FSH or recombinant FSH in polycystic ovary syndrome patients: a prospective randomized analysis of cost-effectiveness. Reproductive BioMedicine Online 2004;9(5):494-9.
6. Loumaye E, Martineau I, Piazzi A, O'Dea L, Ince S, Howles C, et al. Clinical assessment of human gonadotrophins produced by recombinant DNA technology. Human Reproduction 1996;11(1):95-107.
7. McFaul P, Traub A, Thomson W. Treatment of clomiphene citrate-resistant polycystic ovarian syndrome with pure follicle-stimulating hormone or human menopausal gonadotropin. Fertility and Sterility 1990;53(5):792-7.
8. Platteau P, Nyboe Andersen A, Balen A, Devroey P, Sørensen P, Helmgaard L, et al. Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II. anovulatory infertility: a randomized controlled study. Human Reproduction 2006;21(7):1798-1804.
9. Revelli A, Poso F, Gennarelli G, Moffa F, Grassi G, Massobrio M. Recombinant versus highly-purified, urinary follicle-stimulating hormone (r-FSH vs. HP-uFSH) in ovulation induction: a prospective, randomized study with cost-minimization analysis. Reproductive Biology and Endocrinology 2006;4:38-44.
10. Sagle M, Hamilton-Fairley D, Kiddy D, Franks S. A comparative, randomized study of low-dose human menopausal gonadotropin and follicle-stimulating hormone in women with polycystic ovarian syndrome. Fertility and Sterility 1991;55(1):56-60.
11. Seibel MM, McArdle C, Smith D, Taymor ML. Ovulatoin induction in polycystic ovary syndrome with urinary follicle-stimulating hormone or human menopausal gonadotropin. Fertility and Sterility 1985;43(5):703-7.
12. Szilágyi A, Bártfai G, Mánfai A, Koloszár S, Pál A, Szabó I. Low-dose ovulation induction with urinary gonadotrophins or recombinant follicle stimulating hormone in patients with polycystic ovary syndrome. Gynaecological Endocrinology 2004;18(1):17-22.
13. Taketani Y, Kelly E, Yoshimura Y, Hoshiai H, Irahara M, Mizunuma H, et al. Recombinant follicle stimulating hormone (follitropin alfa) versus purified urinary follicle stimulating hormone in a low dose step up regimen to induce ovualtion in japanese women with anti-estrogen-ineffective oligo- or anovulatory infertility. Reproductive Medicine and Biology 2010;9:99-106.
14. Yarali H, Bukulmez O, Gurgan T. Urinary follicle-stimulating hormone (FSH) versus recombinant FSH in clomiphene citrate-resistant, normogonadotropic, chronic anovulation: a prospective randomized study. Fertility and Sterility 1999;72(2):276-81.
15. Homburg R, Eshel A, Kilborn J, Adams J, Jacobs HS. Combined luteinizing hormone releasing hormone analogue and exogenous gonadotrophins for the treatment of infertility associated with polycystic ovaries. Human Reproduction 1990;5(1):32-5.
16. Jacobs H, Porter R, Eshel A, Craft I. Profertility uses of LHRH agonist analogues. In: Vickery BH, Nestor JJ Jr editor(s). LHRH and its Analogues; Contraceptive and Therapeutic Application. Part 2. Lancaster: MTP Press, 1987:303-22.
17. Larsen T, Larsen JF, Schiøler V, Bostofte E, Felding C. Comparison of urinary human follicle-stimulating hormone and human menopausal gonadotropin for ovarian stimulation in polycystic ovarian syndrome. Fertility and Sterility 1990;53(3):426-31.
18. Ricci G, Cerneca F, Simeone R, Pozzobon C, Guarnieri S, Sartore A, et al. Impact of highly purified urinary FSH and recombinant FSH on haemostasis: an open-label, randomized, controlled trial. Human Reproduction 2004;19(4):838-48.
19. Adams J, Polson DW, Franks S. Prevelance of polycystic ovaries in women with anovulation and idiopathic hirsutism. British Medical Journal (Clinical Research ed.) 1986;293(6543):355-9.
20. Albano C, Smitz J, Camus M, Coelingh Bennink H, Van Steirteghem AC, Devroey P. Pregnancy and birth in an in-vitro fertilization cycle after controlled ovarian stimulation in a women with a history of allergic reaction to human menopausal gonadotrophin. Human Reproduction 1996;11(8):1632-4.
21. Andersen CY, Westergaard LG, Van Wely M. FSH isoform composition of commercial gonadotrophin preparations: a neglected aspect?. Reproductive Biomedicine Online 2004;9(2):231-6.
22. Baenziger JU, Green ED. Pituitary glycoprotein hormone oligosaccharides: structure, synthesis and function of asparagine-linked oligosaccharides on lutropin, follitropin and thyrotropin. Biochimica et Biophysica Acta 1988;947(2):287-306.
23. Balen AH. Ovulation induction in the management of anovulatory polycystic ovary syndrome. Molecular and Cellular Endocrinology 2013;373(1-2):77-82.
24. Bergh C. What are the clinical benefits of recombinant gonadotrophins? Recombinant follicle stimulating hormone. Human Reproduction 1999;14(6):1418-20.
25. Biffoni M, Battaglia A, Borrelli F, Cantelmo A, Galli G, Eshkol A. Allergenic potential of gonadotrophic preparations in experimental animal: Relevance of purity. Human Reproduction 1994;9(10):1845-8.
26. De Leeuw R, Mulders J, Voortman G, Rombout F, Damm J, Kloosterboer L. Structure-function relationship of recombinant follicle stimulating hormone (Puregon). Molecular Human Reproduction 1996;2(5):361-9.
27. Farquhar C, Brown J, Marjoribanks J. Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2012, Issue 6. [DOI: 10.1002/14651858.CD001122.pub4]
28. Gemzell CA, Diczfalusy E, Tillinger G. Clinical effect of human pituitary follicle-stimulating hormone (FSH). Journal of Clinical Endocrinology and Metabolism 1958;18(12):1333-48.
29. Golan A, Ron-el R, Herman A, et al. Ovarian hyperstimulation syndrome: an update review. Obstetrical & Gynecological Survey 1989;44:430-440.
30. Gray CJ. Glycoprotein gonadotrophins. Structure and synthesis. Acta Endocrinologica. Supplementum 1988;288:20-7.
31. Hard K, Mekking A, Damm JB, Kamerling JP, De Boer W, Wijnands RA, et al. Isolation and structure determination of the intact sialylated N-linked carbohydrate chains of recombinant human follitropin (hFSH) expressed in Chinese Hamster ovary cells. European Journal of Biochemistry 1990;193(1):263-71.
32. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
33. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
34. Howles CM. Genetic engineering of human FSH (Gonal F). Human Reproduction Update 1996;2(2):172-91.
35. Jewelewicz R, Dyrenfurth I, Warren MP, Van de Wiele RL. Gonadotrophin therapy. Female Infertility. Amsterdam: Excerpta Medica, 1973.
36. Keene JL, Matzuk MM, Otani T, Fauser BC, Galway AB, Hsueh AJ, et al. Expression of biologically active human follitropin in Chinese hamster ovary cells. Journal of Biological Chemistry 1989;264(9):4769-75.
37. Lambert A, Rodgers M, Mitchell R, Wood AM, Wardle C, Hilton B, et al. In-vitro biopotency and glycoform distribution of recombinant human follicle stimulating hormone (Org 32489), Metrodin and Metrodin-HP. Human Reproduction 1995;10(7):1928-35.
38. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326(7400):1167-70.
39. Lunenfeld B, Menzi A, Volet B. Effetti clinici della gonadotropina umana della post-menopausa. La Rassegna di Clinica, Terapia e Scienze Affini 1960;59:213-6.
40. Nahuis M, Van der Veen F, Oosterhuis J, Mol BW, Hompes P, Van Wely M. Review of the safety, efficacy, costs and patient acceptability of recombinant follicle-stimulating hormone for injection in assisting ovulation induction in infertile women. International Journal of Women's Health 2009;1:205-11.
41. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction 2004;19(1):41-7.
42. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility 2004;81(1):19-25.
43. Stockell Hartree AS, Renwick AG. Molecular structures of glycoprotein hormones and functions of their carbohydrate components. Biochemical Journal 1992;287(Part 3):665-79.
44. Vail A, Gardener E. Common statistical errors in the design and analysis of subfertility trials. Human Reproduction 2003;18(5):1000-4.
45. Wide L. Isoforms of human gonadotrophins under different physiological conditions. In: Kahn JA editor(s). Gonadotrophin Isoforms: Facts and Future. Copenhagen: Ciconia Foundation, 1997:43-8.
46. Wilson CA, Leigh AJ, Chapman AJ. Gonadotrophin glycosylation and function. Journal of Endocrinology 1990;125(1):3-14.
47. Yen SS. The polycystic ovary syndrome. Clinical Endocrinology 1980;12:177-207.
48. Youssef MA, Van der Veen F, Al-Inany HG, Mochtar MH, Griesinger G, Nagi Mohesen M, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database of Systematic Reviews 2014, Issue 10. [DOI: 10.1002/14651858.CD008046.pub4]
49. Bayram N, Van Wely M, Van Der Veen F. Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2001, Issue 2. [DOI: 10.1002/14651858.CD002121]
50. Nugent D, Vanderkerchove P, Hughes E, Arnot M, Lilford R. Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD000410]